Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal stem cells for COVID-19 pneumonitis
ChiCTR2000029990Phase 2Recruiting
- Sponsor
- Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences
- Start
- Jan 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of human mesenchymal stem cells in coronavirus pneumonia and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences. Primary endpoint: Improved respiratory system function (blood oxygen saturation) recovery time. Started Jan 2020; status: recruiting.
02
Drugs
human mesenchymal stem cells
03
Conditions
coronavirus pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000029990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029990.